Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Simcere Pharmaceutical Co., Ltd.
With
Shanghai Xianxiang Medical Technology Co., Ltd.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female patients, \>/=18 years of age;
epithelial ovarian, fallopian tube or primary peritoneal cancer;
platinum-resistant disease (disease progression within \<6 months of platinum therapy)
Eastern Cooperative Oncology Group（ECOG）performance status of 0-1
You may not be if
non-epithelial tumours
ovarian tumours with low malignant potential
Received 1 line of systemic therapy for ovarian cancer following platinum resistance and/or \> 1 line of non-platinum systemic therapy prior to platinum resistance.
prior radiotherapy to the pelvis or abdomen
Clareo Health | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
